TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02438943

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Audit
Description: An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
Study: NCT01609647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
Study: NCT02438943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Intervention
Description: Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
Study: NCT02745613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8 weeks of combined exercise intervention
Description: The subjects will undergo an 8 week combined exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8 weeks of combined exercise intervention
Description: The subjects will undergo an 8 week combined exercise intervention
Study: NCT03533114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-258
Description: Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
Study: NCT04408742

Intervention type: OTHER
Intervention: pain
Description: Lower abdominal and low back pain was questioned. Pain intensity was evaluated with a 0 to 10 cm visual analog scale (VAS): 0 indicated no pain and 10 indicated the worst imaginable pain \[18\]. Pain that developed during the activity was also questioned and stated as pain+ activity. A higher score indicates a more severe pain.
Study: NCT02520115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Given PO
Study: NCT00421122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Description: inhalation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide (Pulmicort)
Description: inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline sulfate (Bricasol)
Description: inhalation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbutaline sulfate (Bricasol)
Description: inhalation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbutaline sulfate (Bricasol)
Description: inhalation therapy
Study: NCT06041542

Intervention type: DIAGNOSTIC_TEST
Intervention: 10-second hand grip and release test
Description: To grip and release hand in ten seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: 10-second hand grip and release test
Description: To grip and release hand in ten seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: 10-second hand grip and release test
Description: To grip and release hand in ten seconds
Study: NCT02659280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjunct Therapy
Description: Store and Forward Tele-heath

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Outpatient Physical Therapy
Study: NCT04541953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Therapy
Description: Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises and stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Rehabilitation Therapy
Description: Range of motion exercises and stretching
Study: NCT04459000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS + maternal Attachment Biobehavioral Catchup home visiting model
Description: Mothers receive up to 12 home visits from a licensed therapist focused on attachment and positive parenting in substance exposed babies. This includes 1 prenatal home visit and up to 11 postnatal visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STARs Only
Description: Participants receive prenatal care in the STAR clinic (a clinic specifically designed to support mothers with substance abuse who are at risk of losing their children to child welfare at birth).
Study: NCT04439227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study: NCT04488198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
Study: NCT04284592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning (RIP)
Description: The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
Study: NCT00711555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant, ondansetron, dexamethasone
Description: On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting.
Study: NCT04488198

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Acupuncture
Description: Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
Study: NCT03655470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning
Description: Safety planning is an individual coping intervention to reduce suicidal risk in adolescents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
Study: NCT03840395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal Electrical Stimulation (PES)
Description: The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pharyngeal Electrical Stimulation (PES)
Description: The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
Study: NCT02098213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate spa treatment
Description: soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Late Spa treatment
Description: soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
Study: NCT00638235

Intervention type: DEVICE
Intervention: AMS Apogee™ with IntePro
Description: Mesh implant for posterior wall pelvic organ prolapse
Study: NCT04232917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LPAPI®
Description: Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00991094

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00638235

Intervention type: DEVICE
Intervention: AMS Apogee™ with Intexen LP
Description: Graft implant for posterior wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Perigee™ with IntePro
Description: Mesh implant for anterior wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Perigee™ with IntePro Lite
Description: Mesh implant for anterior wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Apogee™ with IntePro Lite
Description: Mesh implant for posterior wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Elevate™ Apical & Posteiror with IntePro Lite
Description: Mesh implant for apical and posterior wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Elevate™ Apical & Posteiror with IntXen LP
Description: Graft implant for apical and posterior wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)
Description: Mesh implant for anteiror and apical wall pelvic organ prolapse

Intervention type: DEVICE
Intervention: AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)
Description: Mesh implant for anteiror and apical wall pelvic organ prolapse
Study: NCT02905383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
Study: NCT03759015

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
Study: NCT03635437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Aminobutyric Acid (GABA)
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Aminobutyric Acid (GABA)
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
Study: NCT02218099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: Oral
Study: NCT04343586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light phototherapy
Description: Phototherapy- Wavelength: 417±15 nm
Study: NCT02849275

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Free 1% Milk
Description: isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Treatment
Description: Probiotic treatment, consumed once daily, over 4-5 weeks.
Study: NCT05030402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tens, exercise, SW
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tens, exercise, SW
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
Study: NCT03635437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Aminobutyric Acid (GABA)
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
Study: NCT00466622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets x 2 daily. Orally from Weifa
Study: NCT01676883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance
Description: removal of calluses and corns by pedicure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography
Study: NCT01577511

Intervention type: BIOLOGICAL
Intervention: Samples and follow up
Description: Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months
Study: NCT02218099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT04529642

Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial Measurement Unit evaluation
Description: An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial Measurement Unit evaluation
Description: An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
Study: NCT02185781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous NK cells infusions
Description: Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance.
Study: NCT04810923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: intra-articular i-PRF injection after arthrocentesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
Study: NCT02881320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Adult Strength)
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Adult Strength)
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Adult Strength)
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablets administered orally once daily without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablets administered orally once daily without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.
Study: NCT02940743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Therapy (SCT)
Description: This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
Study: NCT02197533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written List
Description: Written list of seven management strategies for OAB to be produced during verbal discussion about management.
Study: NCT02881320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.
Study: NCT01775215

Intervention type: RADIATION
Intervention: Cardiac I123-MIBG Scintigraphy

Intervention type: RADIATION
Intervention: Cardiac I123-MIBG Scintigraphy

Intervention type: OTHER
Intervention: Cardiac MRI

Intervention type: OTHER
Intervention: Cardiac MRI

Intervention type: OTHER
Intervention: Stress and rest Echocardiogram

Intervention type: OTHER
Intervention: Stress and rest Echocardiogram

Intervention type: OTHER
Intervention: High Sensitivity Troponin I

Intervention type: OTHER
Intervention: High Sensitivity Troponin I

Intervention type: OTHER
Intervention: Brain Natriuretic Peptide
Study: NCT02881320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
Study: NCT02555787

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study: NCT04469881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR
Description: Participants will be asked to do the following things:~1. Wear VR goggles for the duration of the surgery~2. Answer questions about their experience with the VR goggles~3. Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital
Study: NCT01241695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200 ml per day, treatment period: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200 ml per day, treatment period: 12 weeks